Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Darbepoetin alfa Product Approval Information - Licensing Action 9/17/01

Proper name: Darbepoetin alfa
Tradename: Aranesp
Manufacturer: Amgen, Inc, Thousand Oaks, CA, License #1080
Indication for Use: Treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis
Approval Date: 9/17/2001
Type of submission: Biologics license application


Approval Letter (PDF)

Label (PDF)

Patient Package Insert (PDF)

CMC Review (PDF)

Medical Officer (PDF)

Clinical Pharm (PDF)

Statistical (PDF)

Immunogenicity (PDF)

Toxicology (PDF)

Page Last Updated: 10/04/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English